Lets hope it works for the sufferers of haemophilia.A patient in the US has become the first person to receive the world’s most expensive drug, Hemgenix, as CSL begins to commercialise its treatment for haemophilia B.
At $3.5m a shot, Hemgenix aims to effectively cure patients in one dose, replacing regular infusions that can cost more than $20m over an adult lifetime.
Analysts had been anticipating a quicker launch of the drug, which the US Food and Drug Administration approved last November, and initially expected that it would send CSL shares soaring above $300 again.
Part of the reason why commercialisation has been slower than expected is that health funds have been reviewing coverage of Hemgenix on a case-by-case basis.
But CSL has confirmed that more than 60 per cent of the US population has health policies covering the cost of the one-time only gene therapy.
An Australian launch is understood to be several years away, with the drug currently before the Therapeutics Goods Administration.
CSL Behring vice president for North America, Bob Lojewski, highlighted the cost savings to the health system, despite the high upfront price.
“Discussions between CSL Behring and the payer community on the value proposition offered for Hemgenix have been positive, which is reflected in the policies that have been written,” Mr Lojewski said.
“As part of our longtime promise to patients, CSL Behring is thrilled to mark this latest milestone of the first commercial patient having received Hemgenix and look forward to continuing to deliver this paradigm-shifting treatment to the haemophilia B community.”
Haematologist Matthew Ryan administered the first dose of the drug to patient in Wisconsin and said it was a “long-awaited advancement” for people with haemophilia B – a debilitating illness that plagued European royalty in the 19th and early 20th centuries and affects about one in 40,000 males today.
Fallen enough for me to take a parcel.This has been quite a slide since the update. And not a conviction yet that a base has formed.
View attachment 159355
I wish that were so , but I now have to reconsider my woolly -thinking $ 250 target.more downside to come
No worries. If I was a day trader, I'd be looking at CSL from a different angle too.I wish that were so , but I now have to reconsider my woolly -thinking $ 250 target.
All the big volumes today went through in the after market trading.
Instos !
May have to bite the bullet real soon . looks like the bottom is pretty near .
Well 17/6/23 to Today 12/7/23 = the predictable 2nd 10% drop - Only one more small drop to come.....May as well butt in again on the CSL conversation.
IMO, Irrational Exhuberance has always ruled CSL.
IMO CSL was Overvalued back on 17/12/21 when their SP was at $273.00, their IV at that date was $176 to $215.
As at today 17/6/23 the CSL IV is well below $200,
So IMO another two 10%+ drops are well overdue.
The sheep notice that someone sneezes, then within a short time the sheep hear that CSL has developed a vaccine or whatever, So, then the the Expert Brokers an Analysts of the world issue rave reviews, so the sheep do what sheep always do, they chase the SP up to ridiculous heights.
Then a few months later the whole process repeats.
CSL are only doing their job, so the Analysts should not be ramping the stock for just doing their job.... Grrrrrrrr..
Crawling back into my cave now....
Sorry, forgot to attach the CSL Chart....Well 17/6/23 to Today 12/7/23 = the predictable 2nd 10% drop - Only one more small drop to come.....
An IV done 4/7/23 = $225 to $258..... And that is a pretty generous call.....
Even then CSL will have 8 Resistance lines to cross.....
WATCHOUTDOWNUNDER....
Cheers....
DrB.
Haven't agreed with some of your analysis's but you seem right on point on this one.IMO, FOMO will begin to take hold of CSL from here on....
Don't be a Sheep......
Following the Sheep invariably leads to the Slaughter House...
I Read you.Fear Of Missing Out
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?